Kadcyla 100 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FCRN1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,657
Award facts
- Contract value 100% obligated
- $21,656.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a $21,656.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 100 mg vials of Kadcyla, an oncology therapeutic agent. This delivery order, awarded on December 10, 2025, represents one of numerous orders issued to DMS Pharmaceutical Group under the agency's broader Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The order carries an ultimate completion date of January 2, 2026, with no set-aside designation applied, demonstrating the vendor's competitive capability in unrestricted federal procurement.
DMS Pharmaceutical Group operates as a critical pharmaceutical supplier within the Department of Defense's global healthcare supply chain under its single-award indefinite delivery contract (SPE2DR) with the Defense Logistics Agency, valued at $499.9 billion through December 31, 2036. The PPV-G GEN V program, part of a $30.3 billion acquisition strategy, authorizes the company to supply an extensive portfolio of branded and generic prescription medications, biologics, and medical consumables to military healthcare facilities worldwide. This specific delivery order for Kadcyla exemplifies the vendor's specialized pharmaceutical distribution capabilities supporting DoD oncology treatment requirements across the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FCRN1?
SPE2DR26FCRN1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 10, 2025.
How much is contract SPE2DR26FCRN1 worth?
The government has obligated $21,657 on SPE2DR26FCRN1.
Is contract SPE2DR26FCRN1 an order under another contract?
Yes. SPE2DR26FCRN1 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRN1 competed?
The extent of competition for SPE2DR26FCRN1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award